What's Happening?
SciTech Development, a clinical-stage oncology company, has announced the appointment of Dr. Peter Littrup as Medical Director for Solid Tumors and Joseph Kraus to its Advisory Board. Dr. Littrup, a pioneer in interventional oncology, will guide the clinical strategy
for SciTech's lead therapeutic candidate, ST-001 nanoFenretinide™, as it advances into solid tumor indications. Joseph Kraus, with extensive experience in legal and financial operations, will advise on corporate structure and financing strategies as the company progresses with its Series A funding and clinical trial expansion.
Why It's Important?
These leadership appointments are crucial for SciTech as it seeks to strengthen its clinical and financial strategies. Dr. Littrup's expertise in oncology and image-guided therapies is expected to accelerate the development of ST-001 nanoFenretinide™, potentially broadening its application across various cancer types. Joseph Kraus's role in advising on corporate governance and financing is vital for securing the necessary resources to support SciTech's growth and innovation in cancer therapeutics. The company's focus on nanotechnology-enabled treatments highlights its commitment to advancing more effective and accessible cancer therapies.
